Previous studies have shown that treatment of colorectal cancer cell lines with DNA methyltransferase inhibitors rescues PDLIM2 expression, leading to inhibition of NF-κB activation in a dose-dependent manner and a subsequent reduction in tumor growth (Qu et al., 2010b). Here, PDLIM2 is linked to colorectal cancer.